Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells

Over half of cutaneous melanoma tumors have BRAF(V600E/K) mutations. Acquired resistance to BRAF inhibitors (BRAFi) remains a major hurdle in attaining durable therapeutic responses. In this study we demonstrate that approximately 50–60% of melanoma cell lines with vemurafenib resistance acquired in...

Descripción completa

Detalles Bibliográficos
Autores principales: Misek, SA, Appleton, KM, Dexheimer, TS, Lisabeth, EM, Lo, RS, Larsen, SD, Gallo, KA, Neubig, RR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024013/
https://www.ncbi.nlm.nih.gov/pubmed/31659259
http://dx.doi.org/10.1038/s41388-019-1074-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024013/
https://www.ncbi.nlm.nih.gov/pubmed/31659259
http://dx.doi.org/10.1038/s41388-019-1074-1

Ejemplares similares